Table 4 Process and outcome indicators at baseline and 1-year follow-up
Process and outcome indicators | Baseline | Follow-up | Baseline vs. Follow-up Differencea | Interactionb | |
|---|---|---|---|---|---|
% (n/N) | % (n/N) | OR (95 % CI) | P-value | P-value | |
Intervention | |||||
Process indicators | |||||
Smoking status recorded | 61.5 (160/260) | 90.4 (338/374) | 14.397 (7.987–25.886) | < 0.001 | < 0.001 |
BP measured regularly | 25.0 (65/260) | 71.4 (267/374) | 10.013 (6.642–15.094) | < 0.001 | < 0.001 |
Fasting glucose tested | 13.1 (34/260) | 16.3 (61/374) | 1.393 (0.860–2.255) | 0.178 | 0.800 |
Total cholesterol tested | 8.1 (21/260) | 12.3 (46/374) | 1.781 (1.002–3.165) | 0.049 | 0.423 |
WHO/ISH risk score documented | 0.0 (0/259) | 79.7 (295/370) | - | - | - |
WHO/ISH risk score calculatable | 96.1 (249/259) | 99.7 (369/370) | 13.805 (1.692-112.649) | 0.014 | 0.004 |
High-risk patients | 26.5 (69/260) | 15.0 (56/374) | 0.491 (0.311–0.775) | 0.002 | 0.216 |
BP lowering drug prescribed | 96.5 (251/260) | 97.1 (363/374) | 1.568 (0.596–4.124) | 0.362 | 0.910 |
Statin prescribed for high-risk patients | 23.2 (16/69) | 78.6 (44/56) | 12.640 (4.365–36.599) | < 0.001 | 0.001 |
Aspirin prescribed for high-risk patients | 85.5 (59/69) | 87.5 (49/56) | 0.368 (0.091–1.493) | 0.162 | 0.213 |
Triple therapy prescribed for high-risk patients | 23.2 (16/69) | 76.8 (43/56) | 11.699 (3.947–34.679) | < 0.001 | 0.001 |
Outcome indicators | |||||
BP at normal range | 14.8 (34/229) | 32.5 (118/363) | 3.556 (2.219–5.696) | < 0.001 | < 0.001 |
High-risk patients with BP at normal range | 15.8 (9/57) | 20.4 (11/54) | 1.717 (0.572–5.158) | 0.335 | 0.133 |
Low-risk patients with BP at normal range | 14.5 (25/172) | 34.6 (107/309) | 4.235 (2.438–7.358) | < 0.001 | 0.002 |
Control | |||||
Process indicators | |||||
Smoking status recorded | 73.4 (152/207) | 68.0 (166/244) | 0.395 (0.210–0.743) | 0.004 | |
BP measured regularly | 62.3 (129/207) | 68.9 (168/244) | 1.319 (0.849–2.049) | 0.218 | |
Fasting glucose tested | 22.7 (47/207) | 30.7 (75/244) | 1.554 (0.959–2.519) | 0.074 | |
Total cholesterol tested | 12.1 (25/207) | 15.2 (37/244) | 1.257 (0.681–2.321) | 0.464 | |
WHO/ISH risk score documented | 0.0 (0/203) | 0.4 (1/242) | - | - | |
WHO/ISH risk score calculatable | 99.5 (202/203) | 98.3 (238/242) | 0.185 (0.015–2.328) | 0.192 | |
High-risk patients | 46.9 (97/207) | 41.8 (102/244) | 0.720 (0.479–1.082) | 0.114 | |
BP lowering drug prescribed | 94.7 (196/207) | 95.9 (234/244) | 1.458 (0.586–3.628) | 0.418 | |
Statin prescribed for high-risk patients | 13.4 (13/97) | 15.7 (16/102) | 1.610 (0.529–4.903) | 0.402 | |
Aspirin prescribed for high-risk patients | 89.7 (87/97) | 92.2 (94/102) | 1.437 (0.421–4.903) | 0.562 | |
Triple therapy prescribed for high-risk patients | 13.4 (13/97) | 15.7 (16/102) | 1.610 (0.529–4.903) | 0.402 | |
Outcome indicators | |||||
BP at normal range | 17.8 (36/202) | 13.2 (31/234) | 0.644 (0.370–1.121) | 0.120 | |
High-risk patients with BP at normal range | 22.1 (21/95) | 13.0 (13/100) | 0.571 (0.235–1.389) | 0.216 | |
Low-risk patients with BP at normal range | 14.2 (15/107) | 13.4 (18/134) | 0.877 (0.399–1.926) | 0.744 | |